LACTOLOGY FOUNDATION

Diosmectite (ATC A07BC05) is a natural aluminium–magnesium silicate clay used as an intestinal adsorbent for acute and chronic diarrhea and functional bowel disorders, with negligible gastrointestinal absorption but subject to precautionary restrictions in breastfeeding because of trace heavy‑metal content and limited lactation data.atcddd.fhi+3

ATC A07BC05 overview

ATC code A07BC05 designates diosmectite within the subgroup A07BC “Other intestinal adsorbents,” part of the intestinal adsorbents class A07B among antidiarrheals. The defined daily dose in the ATC/DDD system is 9 g orally, reflecting typical adult use in diarrhea and functional bowel disorders.atcddd.fhi+4

Pharmacology and mechanism

Diosmectite (dioctahedral smectite) is an insoluble clay with a high surface area and strong adsorptive properties, enabling it to bind bacteria, bacterial enterotoxins, viruses, bile salts, and other potentially diarrheogenic substances in the intestinal lumen. It also interacts with mucosal glycoproteins to strengthen and thicken the intestinal mucus barrier, reduces mucolysis, and exerts anti‑inflammatory effects that contribute to improved stool consistency and reduced irritation.pmc.ncbi.nlm.nih+3

Therapeutic indications

Clinically, diosmectite is indicated for treatment of acute diarrhea in adults and in children older than 2 years, as an adjunct to oral rehydration therapy, and for symptomatic treatment of chronic functional diarrhea and pain in functional bowel disorders in adults. Randomized trials in children and adults show that diosmectite reduces stool output, decreases stool frequency, and shortens the duration of acute watery diarrhea episodes, particularly in rotavirus‑positive pediatric cases.pmc.ncbi.nlm.nih+6

Dosing and administration (context for risk)

Typical adult dosing for acute diarrhea is 9 g per day (for example, 3 g three times daily) for about 7 days, with higher initial doses sometimes used at the start of treatment; pediatric dosing is weight‑ and age‑adjusted (for example, 4 sachets per day for 3 days, then 2 sachets daily for 4 days in children over 2 years). Diosmectite is taken orally as a suspension, prepared immediately before use by mixing sachet contents with water or semi‑solid food.acinoedudoc+1

Pharmacokinetics relevant to lactation

Diosmectite is insoluble and not absorbed from the gastrointestinal tract; it acts locally and is excreted unchanged in feces, which theoretically minimizes systemic exposure and milk transfer. However, as a naturally occurring clay, it contains trace amounts of heavy metals such as lead, and regulators have focused on the possibility of lead passage into blood, especially in children and with prolonged use.pubmed.ncbi.nlm.nih+4

Maternal safety and adverse effects

In clinical trials and post‑marketing surveillance, diosmectite has been generally well tolerated, with constipation the most frequently reported adverse reaction, and rare hypersensitivity events (rash, urticaria, pruritus, angioedema). Overdose or prolonged high‑dose use can lead to severe constipation or bezoar formation, and caution is advised in patients with a history of severe chronic constipation.pmc.ncbi.nlm.nih+3

Regulatory and safety alerts in lactation

Regulatory agencies (for example, ANSM, NPRA, HSA) have highlighted concerns about trace lead content in clay‑based medicines and, as a precaution, have restricted Smecta (diosmectite) use to adults and children over 2 years and recommended against use during pregnancy and breastfeeding due to limited data and theoretical heavy‑metal risk. Product information for Smecta formulations explicitly states that use during breastfeeding is “not recommended” rather than contraindicated, reflecting precaution rather than documented harm.hsa+4

Lactation safety assessment

From a toxico‑lactological perspective, the non‑absorption of diosmectite itself suggests negligible direct transfer into human milk; however, the potential systemic passage of trace lead and the absence of dedicated lactation pharmacokinetic studies lead to a cautious stance. Consequently, many guidelines classify diosmectite as a second‑line or avoidable option in breastfeeding, favoring agents with established safety such as loperamide or non‑clay adsorbents when antidiarrheal therapy is needed.hsa+5

Potential effects on the breastfed infant

Direct exposure of the infant to diosmectite via breast milk is expected to be extremely low, given its lack of absorption, so clay‑related toxicity in the infant is unlikely. The main theoretical concern is chronic heavy‑metal exposure (especially lead) if maternal use were prolonged or at high doses, although available clinical safety data have not reported lead poisoning cases in adults treated with standard diosmectite courses.pubmed.ncbi.nlm.nih+4

Practical recommendations in breastfeeding

For breastfeeding women with mild acute diarrhea, first‑line management remains oral rehydration and dietary measures, with non‑clay antidiarrheals preferred when drug treatment is necessary. If diosmectite is considered in a specific case (for example, lack of alternatives or clear benefit anticipated), it should be used at the lowest effective dose for the shortest duration, with informed discussion of regulatory “not recommended” status in lactation and monitoring of both mother and infant for gastrointestinal symptoms and overall well‑being.hsa+5

Role among intestinal adsorbents

Compared with other A07BC adsorbents (pectin, kaolin, attapulgite), diosmectite has the strongest evidence base for reducing stool output and duration of acute watery diarrhea, particularly in children, but carries unique regulatory concerns due to its clay origin and trace heavy‑metal content. Its favorable clinical efficacy and generally benign short‑term safety must therefore be weighed against precautionary breastfeeding restrictions, making it an effective but non‑preferred antidiarrheal in lactating women when safer alternatives are available.pmc.ncbi.nlm.nih+7